LOAN AGREEMENT THIS LOAN AGREEMENT dated this 16th day of March, 2023 between Christopher M Kim of 25 Edinburg Cir, Matawan, NJ 07747 (the “Lender”) andLoan Agreement • August 5th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations • New Jersey
In consideration of the lender loaning certain monies (the Loan”) to the Borrower, and the Borrower repaying the Loan to the Lenser, the parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:
AMENDMENT TO THE AMENDMENT TO THE PROMISSORY NOTEAmendment to the Promissory Note • August 5th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations
THIS AMENDMENT (this “Amendment”) to the Amendment to the Promissory Note, dated as of December 5, 2023 (the “Original Amendment”), which amended the Promissory Note, dated as of June 3, 2022, by and between Apimeds Pharmaceuticals US, Inc. a Delaware corporation (the “Company”) and Inscobee, Inc., a South Korean corporation (the “Holder”), is made and entered into as of June 12, 2024. All capitalized terms not specifically defined in this Amendment shall have the meanings ascribed to them in the Original Amendment.
MURDOCK CAPITAL PARTNERS CORP.Consulting Agreement • August 5th, 2024 • Apimeds Pharmaceuticals US, Inc. • Pharmaceutical preparations
Pursuant to our recent conversations regarding the Think Equity capital raise and IPO Initial Public Offering - for Apimeds Pharmaceuticals US, Inc. (“Apimeds USA”) this letter is to acknowledge and confirm the terms of an advisory and corporate consulting fee agreement (the “consulting agreement”) as follows:
